The metastasis gene osteopontin: a candidate target for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Malignant tumors exhibit uncontrolled growth, bypass senescence, and metastasize.
• Current cancer therapies primarily target cell cycle progression, neglecting key transformation aspects.
• Osteopontin is a critical cytokine for the spread of various cancers.

Purpose of the Study:

• To review and highlight therapeutic strategies targeting osteopontin and its receptors for cancer treatment.
• To emphasize the potential of targeting metastasis-associated molecules due to their restricted expression in healthy tissues.

Main Methods:

• Review of existing research on osteopontin and its receptors (CD44, integrin alpha(V)beta(3)) in cancer.
• Analysis of therapeutic approaches including gene transcription inhibition, antibody blockade, and small molecule inhibitors.
• Evaluation of the role of osteopontin and its receptors in tumor cell dissemination, angiogenesis, and osteolysis.

Main Results:

• Osteopontin expression can be inhibited at transcriptional and post-transcriptional levels.
• Osteopontin protein can be targeted using antibodies or synthetic peptides.
• Receptors CD44 and integrin alpha(V)beta(3) are viable targets for cytotoxic and immunotherapeutic strategies, with integrin alpha(V)beta(3) inhibitors under development.

Conclusions:

• Osteopontin and its receptors are crucial for cancer metastasis and represent attractive therapeutic targets.
• Targeting these extracellular molecules is advantageous due to their limited expression in healthy adults, allowing for potentially safer pharmaceutical interventions.
• Intervention strategies focusing on metastasis mediators offer a promising avenue for novel cancer therapies.